India  

India to consider clinical trials data of two full doses of AstraZeneca vaccine

IndiaTimes Thursday, 26 November 2020
India will consider clinical trial data for the two full-dose Oxford-AstraZeneca Covid-19 vaccine candidate which the firm says has an efficacy of 62% and not the “half plus full” dose regime which is claimed to be up to 90% effective but has attracted criticism for dosing errors.
0
shares
ShareTweetSavePostSend
 
Video Credit: Wibbitz Top Stories - Published
News video: AstraZeneca, 3rd Major COVID-19 Vaccine, Shown to Be Effective and Cheaper

AstraZeneca, 3rd Major COVID-19 Vaccine, Shown to Be Effective and Cheaper 01:10

AstraZeneca, 3rd Major COVID-19 Vaccine, Shown to Be Effective and Cheaper. On Monday, the drugmaker announced the "exciting results" based on an analysis of trials in the U.K. and Brazil. Because the vaccine can be stored at fridge temperatures, it can be distributed around the world using the...

💡 newsR Knowledge: Other News Mentions

AstraZeneca British-Swedish pharmaceutical company

Vaccine manufacturing is lumpy, UK says [Video]

Vaccine manufacturing is lumpy, UK says

Britain's vaccine rollout is limited by a "lumpy" manufacturing process with production changes by Pfizer and a delay by AstraZeneca that could lead to brief supply disruption, Vaccine Deployment Minister Nadhim Zahawi said on Monday. Ciara Lee reports

Credit: Reuters Studio    Duration: 01:24Published
Sao Paulo nurse first to get CoronaVac shot in Brazil [Video]

Sao Paulo nurse first to get CoronaVac shot in Brazil

Monica Calazans, a 54-year-old nurse in Sao Paulo, became on Sunday the first person to be inoculated in Brazil, receiving the Chinese vaccine known as CoronaVac after Brazilian health regulator Anvisa approved emergency use of COVID-19 vaccines from China's Sinovac Biotech Ltd and Britain's AstraZeneca.

Credit: Reuters Studio    Duration: 00:54Published
Easing of lockdown restrictions not before March, says Zahawi [Video]

Easing of lockdown restrictions not before March, says Zahawi

Vaccines minister Nadhim Zahawi has suggested that a gradual easing oflockdown restrictions will not begin before early March. He told BBCBreakfast: “If we take the mid-February target, two weeks after that you getyour protection, pretty much, for the Pfizer/BioNTech, three weeks for theOxford/AstraZeneca, you are protected. “One of the things we don’t know yet,and the deputy chief medical officer Jonathan Van-Tam is on record as saying‘look give me a couple of months and I’ll tell you’, is the impact of thevaccine on transmission rates ie on infecting people. “So there are a numberof caveats that stand in the way of us reopening the economy. “It will begradually, it will be probably through the tiered system but you’re looking atthat sort of period, two to three weeks after the middle of February, afterwe’ve protected the top four cohorts.”

Credit: PA - Press Association STUDIO    Duration: 00:53Published
Nepal: People cheers after approval of Covishield vaccine manufactured in India [Video]

Nepal: People cheers after approval of Covishield vaccine manufactured in India

After Nepal government approved emergency use of Covishield vaccine, people are hoping the pandemic will falter and human lives would be back on track. Nepal's Department of Drug Administration on Friday issued a release giving information on approving Covishield developed by AstraZeneca and Oxford University, which will be manufactured by Serum Institute of India (SII) in India. Drug regulating authority has also specified Serum Institute of India for importers provided with low cost in purchasing and delivery of vaccine to public. Approving the vaccine for conditional purpose, the department has also asked manufacturers or importers to get approval for registration in order to bring the vaccines. Nepal imposed nationwide and partial lockdown for most of 2020 with rise in imported cases which later took the form of local transmission spreading mostly in urban areas and major cities. The nationwide lockdown which started in March 2020 hampered daily life of people as well as businesses. They now expect to thrive with the approval of vaccine. Though the detailed inoculation plan of Nepal Government is yet to be disclosed, a total of 3 companies applied for approval to take steps forward with Serum Institute for import of vaccines. India has already made conditional emergency approval for Covishield manufactured by the Serum Institute. Being one of the largest producers of vaccines at low cost, India has promised to provide vaccine to its neighbours in near future.

Credit: ANI    Duration: 02:39Published

Serum Institute expects WHO emergency approval for AstraZeneca shot soon

The Serum Institute of India expects WHO emergency-use authorization soon for the Oxford University/AstraZeneca coronavirus vaccine, which it is producing for..
IndiaTimes

Coronavirus disease 2019 Coronavirus disease 2019 Disease caused by severe acute respiratory syndrome coronavirus 2

Amid efficacy row, Covaxin gets thumbs-up from Lancet

Amid a raging controversy over the efficacy of Covaxin, India’s first indigenous Covid-19 vaccine, reputed medical journal the Lancet Infectious Diseases on..
IndiaTimes
De Bruyne out for 4-6 weeks, Aguero feeling COVID fatigue - Guardiola [Video]

De Bruyne out for 4-6 weeks, Aguero feeling COVID fatigue - Guardiola

Pep Guardiola says Manchester City will have to live without two of their best players for a while as Kevin De Bruyne and Sergio Aguero are sidelined.

Credit: Reuters - Sports    Duration: 03:29Published
Preparations underway for Aero India 2021 at Yelahanka Airforce Station [Video]

Preparations underway for Aero India 2021 at Yelahanka Airforce Station

The preparations are underway for the 13th edition of Aero India 2021' at Yelahanka Airforce Station. The event will be the first global airshow organised in the COVID era. It offers unique platform to International aviation sector to boost business. Aero India 2021' will be held from Feb 03- Feb 05, 2021

Credit: ANI    Duration: 02:09Published

COVID will be 'with us forever, but controlled', admits government adviser

UK government chief scientific adviser Patrick Vallance has admitted the world will be living with coronavirus - probably forever.
Sky News

You Might Like


Related videos from verified sources

Stocks rally on vaccine news, Yellen speculation [Video]

Stocks rally on vaccine news, Yellen speculation

U.S. stocks started the week on an upswing after another drug company posted positive clinical trial results for a COVID-19 vaccine and reports surfaced that President-Elect Joe Biden plans to nominate..

Credit: Reuters Studio     Duration: 01:56Published
Oxford Covid vaccine upto 90% effective, what are the advantages to this vaccine|Oneindia News [Video]

Oxford Covid vaccine upto 90% effective, what are the advantages to this vaccine|Oneindia News

As the race for a vaccine to put an end to the Coronavirus rages on, the latest drug maker to unveil positive interim data is Astrazeneca, which said on Monday its vaccine for the novel coronavirus..

Credit: Oneindia     Duration: 01:20Published
Coronavirus: Oxford University candidate vaccine is 70% effective [Video]

Coronavirus: Oxford University candidate vaccine is 70% effective

The vaccine was 90% effective if administered at a half dose and then at a full dose and 62% effective if administered in two full doses.View on euronews

Credit: euronews (in English)     Duration: 01:34Published

Related news from verified sources

Mumbai: New and silent COVID-19 symptoms worry doctors

Mumbai: New and silent COVID-19 symptoms worry doctors
The COVID-19 graph has started to slant downwards, but health experts are now concerned about a new trend. Patients are being rushed to emergency rooms without...
Mid-Day

IMA urges the government to collect data of frontline medical warrior as they are at high risk

IMA urges the government to collect data of frontline medical warrior as they are at high risk
While the Indian government has stated that it does not have data on frontline warriors who died fighting COVID-19, a recent study by a medical journal in the UK...
Mid-Day

Mumbai: Unlikely that price cap at hospitals will go, says civic body

After seeing a drop in the city's daily count of COVID-19 cases, private hospitals are hoping that the price cap on 80 per cent of COVID beds will be relaxed...
Mid-Day